Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431438 | 1.00 | KDM4E (0.46) | KDM4EPOLBSMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL2428553 | 0.92 | KDM4E (0.40) | KDM4EPOLBSMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL2428551 | 0.92 | KDM4E (0.40) | KDM4EPOLBSMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL2494792 | 0.88 | KDM4E (0.47) | KDM4EPOLBHPGDIKBKBMAPT | |
| SCHEMBL2494789 | 0.88 | KDM4E (0.47) | KDM4EPOLBHPGDIKBKBMAPT | |
| SCHEMBL2431528 | 0.85 | KDM4E (0.43) | KDM4EPOLBHPGDIKBKBRAB9A | |
| SCHEMBL2431526 | 0.85 | KDM4E (0.43) | KDM4EPOLBHPGDIKBKBRAB9A | |
| SCHEMBL2436809 | 0.85 | GRM4 (0.39) | KDM4EHPGDMAPTRAB9ARXFP1 | |
| SCHEMBL2436807 | 0.85 | GRM4 (0.39) | KDM4EHPGDMAPTRAB9ARXFP1 | |
| SCHEMBL2431492 | 0.82 | MAPT (0.45) | KDM4ESMN1; SMN2HPGDALDH1A1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086966-B1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| EP-2086966-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SmithKline Beecham Corporation (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008059042-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | EIF2AK2, HAVCR2, GTF3C2 | KDM4E 1120/4885POLB 765/4885SMN1; SMN2 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.